CT-XEROX
Today, Xerox announced the launch of its Team Availability App , a quick-to-deploy, real-time solution for organizations that need to understand employee availability and location. Knowing where and whether employees are working is critical to managing flexible work environments, where the percentage of employees sharing time between home and work locations grows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005437/en/
Organizations are actively supporting and investing in technology solutions for a hybrid workforce. A recent global business survey commissioned by Xerox shows 58% of respondents plan to change their work from home policy within the next year. This new acceptance of a hybrid workforce has also revealed technology gaps, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%).
"Managing a distributed workforce during a continued pandemic presents unique challenges no organization has experienced before," said Joanne Collins Smee, executive vice president and chief commercial, SMB and channels officer, Xerox. "Organizations need to know who is available and where so they can make better decisions when allocating resources and work. This tool provides real-time knowledge to managers with distributed employee populations."
Unlike other attendance management tools, which need to plug into IT infrastructure and take weeks to implement, the Team Availability App is ready in just hours. Once populated, the app provides authorized users with customizable and privacy-protected data for strategic decision making. Xerox is rolling out the app across the company to support its Path Forward plans to manage a phased approach to returning to the workplace safely. Xerox is leveraging the app with its own employee population to conduct daily health checks for exposure related to COVID-19. Tracking of this activity allows for a safe and phased return to the workplace.
The U.K.'s prestigious Imperial NHS Trust was the first organization to pilot the Xerox Team Availability App to access the status of essential workers across the Trust and its newly assigned locations at the height of the pandemic.
"It's important for a healthcare provider to know which caregivers are available when to support patients, and that's even more critical in a pandemic," said Linda Watts, joint clinical systems program manager, Imperial NHS Trust & Chelsea & Westminster NHS Foundation Trust, head of health records, Imperial College Healthcare NHS Trust. "The Xerox Team Availability App was deployed at lightning speed, and we got updates from staff on their availability in real-time. As a result, we could always make sure our patients were covered."
The Xerox Team Availability App is a GDPR-compliant SaaS offering with a subscription-based model that allows customers to sign up for as long as required. It's available now on the App Store and Google Play Store .
For more information and additional results from the Xerox Future of Work study, visit www.Xerox.com/MakeNowWork .
About Xerox
Xerox makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .
Xerox Future of Work Survey Methodology
The survey of 600 respondents located in the U.S., Canada, UK, Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision-makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.
Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .
Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005437/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release
Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 14:30:00 CEST | Press release
- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest population of people living with TDT in Europe- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformati
European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary18.9.2025 12:41:00 CEST | Press release
European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head of Structured Finance, before taking on advisory and leadership roles in the securitisation market. Markus Schaber, outgoing Executive Director of EDW Ltd., will remain with the company as Senior Advisor. He commented: “It has been a privilege to lead European DataWarehouse in the UK and contribute to the development of greater transparency in European securitisation markets. I am confident that Nigel’s deep industry knowledge and leadership will strengthen EDW Ltd.’s mission and ensure we continu
Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites18.9.2025 11:20:00 CEST | Press release
Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qualified, with Zycus placed in the Customers’ Choice quadrant — highlighting vendors rated above the market average for both Overall Experience and User Interest & Adoption. Recognition Backed by Customer Experience According to the report, Zycus achieved: 4.6 out of 5 Overall Rating, based on 67 peer reviews as of June 30, 2025. 95% willingness to recommend score – reflecting customer trust and satisfaction. Ratings across Product Capabilities, Sales Experience, Deployment, and Support, each above 4
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 11:00:00 CEST | Press release
Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom